Altered huntingtin−chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease
Disease Models & Mechanisms · 2025
DOI: 10.1242/dmm.052282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2025. Verfasst von Jocelynn R Pearl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Systems Biology, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Huntington Disease, Huntingtin Protein, Chromatin, Epigenesis, Genetic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CHDI Foundation, Huntington Society of Canada, National Science Foundation.
Abstract (Originalsprache)
While progressive striatal gene expression changes and epigenetic alterations are a prominent feature of Huntington's disease (HD), the mechanistic basis remains poorly understood. Using chromatin immunoprecipitation and sequencing (ChIP-seq), we show that the huntingtin protein (HTT) reproducibly occupies specific locations in the mouse genome. Striatal HTT ChIP-seq peaks were enriched in coding regions of spiny projection neuron identity genes that were found to have reduced expression in HD patients and mouse models, and had reduced occupancy in expanded polyglutamine HTT knock-in mice (HttQ111/Q111). By contrast, HTT occupancy was depleted near genes that are upregulated in HD. ChIP-seq of striatal histone modifications revealed genotype-specific colocalization of HTT with active chromatin marks and enhancer of zeste homolog 2 (EZH2), a key enzymatic component of the PRC2 complex. In the vicinity of genes that are differentially regulated in HD, greater HTT occupancy in HttQ111/Q111 vs wild-type mice was associated with increased EZH2 occupancy, increased H3K4me3 levels and decreased H3K27me3 levels. Our study suggests that HTT−chromatin interactions may play a role in organizing chromatin and promoting cell type-specific gene expression, with HTT occupancy predicting transcriptional dysregulation in HD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Systems Biology, Seattle, WA 98109, USA.
- Molecular & Cellular Biology Graduate Program, University of Washington, Seattle, WA 98195, USA.
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Behavioral Neuroscience Program, Department of Psychology, Western Washington University, Bellingham, WA 98225, USA.
- Department of Neurology, University of Washington, Seattle, WA 98195, USA.
- Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.
ORCID-Profile: Jocelynn R Pearl, Amol C Shetty, Jeffrey P Cantle, Dani E Bergey, Robert M Bragg, Sydney R Coffey, Holly B Kordasiewicz, Leroy E Hood, Nathan D Price, Seth A Ament, Jeffrey B Carroll
Förderung
- CHDI Foundation
- Huntington Society of Canada
- National Science Foundation
- University of Washington
Zitieren
APA
Pearl, J. R., Shetty, A. C., Cantle, J. P., Bergey, D. E., Bragg, R. M., Coffey, S. R., Kordasiewicz, H. B., Hood, L. E., Price, N. D., Ament, S. A., & Carroll, J. B. (2025). Altered huntingtin−chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052282
Vancouver
Pearl JR, Shetty AC, Cantle JP, Bergey DE, Bragg RM, Coffey SR, et al. Altered huntingtin−chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease. Disease Models & Mechanisms. 2025. doi:10.1242/dmm.052282
BibTeX
@article{Pearl2025,
author = {Pearl, Jocelynn R and Shetty, Amol C and Cantle, Jeffrey P and Bergey, Dani E and Bragg, Robert M and Coffey, Sydney R and Kordasiewicz, Holly B and Hood, Leroy E and Price, Nathan D and Ament, Seth A and Carroll, Jeffrey B},
title = {Altered huntingtin−chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease},
journal = {Disease Models & Mechanisms},
year = {2025},
doi = {10.1242/dmm.052282}
}
EUVIMED